Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3)

被引:0
作者
Yan Li
Michel Delamar
Patricia Busca
Guillaume Prestat
Laurent Le Corre
Laurence Legeai-Mallet
RongJing Hu
Ruisheng Zhang
Florent Barbault
机构
[1] Lanzhou University,Department of Chemistry
[2] Univ Paris Diderot,ITODYS, UMR CNRS 7086
[3] Sorbonne Paris Cité,UMR 8601 CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques
[4] Université Paris Descartes,INSERM U781, Institut Imagine, Hôpital Necker
[5] Université Paris Descartes,Enfants Malades
[6] Sorbonne Paris Cité,School of Information Science and Engineering
[7] Lanzhou University,undefined
来源
Journal of Computer-Aided Molecular Design | 2015年 / 29卷
关键词
Targeted molecular dynamics; FGFR3; Tyrosine kinase; DFGout; Inactivation process; Conformational change; Molecular docking; Induced-fit effect;
D O I
暂无
中图分类号
学科分类号
摘要
Tyrosine kinases are a wide family of targets with strong pharmacological relevance. These proteins undergo large-scale conformational motions able to inactivate them. By the end of one of these structural processes, a new cavity is opened allowing the access to a specific type of inhibitors, called type II. The kinase domain of fibroblast growth factor receptor 3 (FGFR3) falls into this family of kinases. We describe here, for the first time, its inactivation process through target molecular dynamics. The transient cavity, at the crossroad between the DFGout and Cα helix out inactivation is herein explored. Molecular docking calculations of known ligands demonstrated that type II inhibitors are able to interact with this metastable transient conformation of FGFR3 kinase. Besides, supplemental computations were conducted and clearly show that type II inhibitors drive the kinase inactivation process through specific stabilization with the DFG triad. This induced-fit effect of type II ligands toward FGFR3 might be extrapolated to other kinase systems and provides meaningful structural information for future drug developments.
引用
收藏
页码:619 / 641
页数:22
相关论文
共 452 条
  • [1] Mannig G(2002)The protein kinase complement of the human genome Science 298 1912-1934
  • [2] Whyte DB(2003)Genomic analysis of the eukaryotic protein kinase superfamily: a perspective Genome Biol 4 111-315
  • [3] Martinez R(2002)Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov 1 309-2694
  • [4] Hunter T(2010)Through the “gatekeeper door”: exploiting the active kinase conformation J Med Chem 53 2681-144
  • [5] Sudarsanam S(2009)A conserved protonation-dependent switch controls drug binding in the Abl kinase Proc Natl Acad Sci USA 106 139-11
  • [6] Hanks SK(1998)The eleventh Datta lecture. The structural basis for substrate recognition and control by protein kinases FEBS Lett 430 1-282
  • [7] Cohen P(2002)The conformational plasticity of protein kinases Cell 209 275-14753
  • [8] Zuccotto F(2013)Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases J Am Chem Soc 135 14741-1669
  • [9] Ardini E(2013)Explaining why Gleevec is a specific and potent inhibitor of Abl kinase Proc Natl Acad Sci USA 110 1664-14762
  • [10] Casale E(2014)Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity J Am Chem Soc 136 14753-512